No connection

Search Results

HIND vs HKPD

HIND
Vyome Holdings, Inc.
BEARISH
Price
$2.19
Market Cap
$15.4M
Sector
Healthcare
AI Confidence
95%
HKPD
Cellyan Biotechnology Co., Ltd
BEARISH
Price
$0.62
Market Cap
$14.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
HIND
--
HKPD
--
Forward P/E
HIND
--
HKPD
--
P/B Ratio
HIND
5.3
HKPD
1.33
P/S Ratio
HIND
48.08
HKPD
0.89
EV/EBITDA
HIND
-4.29
HKPD
-12.41

Profitability

Gross Margin
HIND
68.43%
HKPD
8.8%
Operating Margin
HIND
-3707.35%
HKPD
2.96%
Profit Margin
HIND
0.0%
HKPD
-4.29%
ROE
HIND
--
HKPD
-13.38%
ROA
HIND
-43.58%
HKPD
-3.94%

Growth

Revenue Growth
HIND
-40.5%
HKPD
-35.7%
Earnings Growth
HIND
--
HKPD
-83.1%

Financial Health

Debt/Equity
HIND
0.01
HKPD
0.44
Current Ratio
HIND
1.99
HKPD
2.93
Quick Ratio
HIND
1.86
HKPD
2.51

Dividends

Dividend Yield
HIND
--
HKPD
--
Payout Ratio
HIND
0.0%
HKPD
0.0%

AI Verdict

HIND BEARISH

Vyome Holdings (HIND) presents a high-risk profile characterized by a catastrophic collapse in share price (-96.1% over 1 year) and severe operational inefficiency. While the Piotroski F-Score of 5/9 suggests a 'stable' baseline in terms of basic financial structure, this is overshadowed by an operating margin of -3707.35% and a massive earnings miss of -2736.4%. The company is trading at an unsustainable Price/Sales ratio of 48.08 despite revenue declining by 40.5% YoY, indicating a complete disconnect between valuation and fundamental performance.

Strengths
Very low leverage with a Debt/Equity ratio of 0.01
Strong Gross Margin of 68.43%, typical for biotechnology
Adequate short-term liquidity with a Current Ratio of 1.99
Risks
Extreme operational losses (Operating Margin -3707.35%)
Significant revenue contraction (-40.50% YoY)
Severe price devaluation, trading near 52-week lows after a 96% drop
HKPD BEARISH

HKPD presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive growth momentum. While the company maintains a strong liquidity position with a current ratio of 2.93 and low debt, these strengths are overshadowed by a severe collapse in fundamentals, including a 35.7% YoY revenue decline and an 83.1% drop in earnings. The technical trend is purely bearish (0/100), and the stock has lost nearly 78% of its value over the last five years, indicating a long-term structural decline.

Strengths
Strong short-term liquidity (Current Ratio: 2.93)
Low leverage (Debt/Equity: 0.44)
Low Price-to-Sales ratio (0.89)
Risks
Severe revenue contraction (-35.70% YoY)
Catastrophic earnings decline (-83.10% YoY)
Negative Return on Equity (-13.38%)

Compare Another Pair

HIND vs HKPD: Head-to-Head Comparison

This page compares Vyome Holdings, Inc. (HIND) and Cellyan Biotechnology Co., Ltd (HKPD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile